Dicerna Pharmaceuticals, a US-based biopharmaceutical company which is developing RNA interference (RNAi)-based therapeutics, has closed a $60m series C financing.  The round was led by new investor, private investment bank RA Capital, with the participation of new investors, investments firms Brookside Capital, Deerfield, and Omega Funds.  All of Dicerna’s existing institutional investors also particpated: Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One, the corporate venture capital arm of pharmaceutical company GlaxoSmithKline (GSK).

Previously, Dicerna raised $25m…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?